SKAN, pioneer company in the field of cleanroom equipment and isolator design, acquires the majority stake of the leading provider of filling operations in the area of cell and gene therapies.
On 01 October, after years of successful collaboration, SKAN acquired the majority stake of Aseptic Technologies (AT). Since 2011, the Swiss isolator manufacturer owns shares in the company, which was founded more than 10 years ago by GSK as a startup in Belgium to develop a novel filling method, closed vial filling. Since then, Aseptic Technologies has become very successful in the area of cell and gene therapy and today is one of the leading providers.
Thomas Huber, CEO of SKAN Group, is looking forward to the close collaboration: "Aseptic Technologies is a perfect match for the SKAN Group. With the closed vial, they expand our portfolio with the smallest isolator in the world and thus extend our know-how from the indirectly product contacting isolator to the directly product contacting vial.”
Patrick Balériaux, CEO of AT, sees the following advantages in the cooperation: "For Aseptic Technologies, the most important in working with SKAN is to have a strong partner with a good fit of products, bringing a long and well recognized experience in our industry together with a global presence to support the deployment of the Closed Vial® Technology to our clients.
SKAN was founded in 1968 with headquarters in Allschwil, near Basel, Switzerland and employs approximately 800 experts for pharmaceutical process equipment, qualification and life cycle support in seven locations worldwide.